Clinical Trial: Mucopolysaccharidosis (MPS) VI Clinical Surveillance Program (CSP)

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Observational

Official Title: MPS VI Clinical Surveillance Program (CSP)

Brief Summary: The objectives of this program are: to further characterize the natural progression of MPS VI disease; to generate and disseminate information on the care and management of MPS VI patients to clinical and medical professionals; to provide a resource to physicians and patients by providing information for optimizing patient care based on aggregate data; to characterize the clinical response to long-term Naglazyme® (galsulfase) treatment; to further characterize the long-term safety of Naglazyme® treatment.

Detailed Summary:
Sponsor: BioMarin Pharmaceutical

Current Primary Outcome: To further characterize the natural progression of MPS VI disease, irrespective of treatment modality and to evaluate efficacy and safety treatment with Galsulfase. [ Time Frame: at least 15 years ]

Original Primary Outcome:

Current Secondary Outcome:

Original Secondary Outcome:

Information By: BioMarin Pharmaceutical

Dates:
Date Received: September 13, 2005
Date Started: July 2005
Date Completion: December 2020
Last Updated: April 19, 2017
Last Verified: April 2017